Dermata Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for DRMA, updated each market day.
DRMA AI Sentiment
AI predicts Dermata Therapeutics, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Dermata Therapeutics, Inc. Common Stock
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Sector
Exchange
Market Cap
$4,866,793
Cap Tier
Employees
9
Headquarters
SAN DIEGO, CA
Listed Since
Aug. 13, 2021
Website
DRMA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
DRMA Volatility
Dermata Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
